CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical hold on the Company’s aldoxorubicin clinical trials. Enrollment and dosing of new patients is now permitted after study sites’ Institutional Review Boards (IRBs) approve the revised trial protocols. “CytRx developed modified study parameters intended to avoid potential risks, while allowing the company to evaluate the therapeutic impact of aldoxorubicin for pat… Read more »

Shares of Cytrx closed last Friday at $3.32 . CYTR has a 1-year high of $8.35 and a 1-year low of $2.08. The stock’s 50-day moving average is $2.72 and it’s 200-day moving average is $2.95.

CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.